Nuo Therapeutics, Inc.
AURX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.85 | 27.58 | -0.01 | 0.00 |
| FCF Yield | -3.75% | -13.72% | -6.28% | -429.16% |
| EV / EBITDA | -26.88 | -7.34 | -18.83 | 0.00 |
| Quality | ||||
| ROIC | -362.56% | -244.70% | -121.55% | 17.35% |
| Gross Margin | 77.82% | 79.28% | 82.88% | 0.00% |
| Cash Conversion Ratio | 0.96 | 1.00 | 1.17 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 129.97% | – | – | -100.00% |
| Free Cash Flow Growth | 24.83% | 15.69% | -28,865.68% | -32.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.22 | 0.55 | 0.00 |
| Interest Coverage | 0.00 | -1,001.98 | -1,578.98 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.01 | 0.60 | 0.08 | 0.00 |
| Cash Conversion Cycle | -16.50 | -384.94 | -2,695.53 | 0.00 |